F‑box proteins involved in cancer‑associated drug resistance (Review)
- Authors:
- Jian Gong
- Yuqian Zhou
- Deliang Liu
- Jirong Huo
-
Affiliations: Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China - Published online on: April 16, 2018 https://doi.org/10.3892/ol.2018.8500
- Pages: 8891-8900
This article is mentioned in:
Abstract
 |
 |
 |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Z, Huang Y, He H and Ni J: Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling. Mol Med Rep. 12:3916–3922. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lippert TH, Ruoff HJ and Volm M: Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 58:261–264. 2008.PubMed/NCBI | |
|
Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH and Wiemer EA: Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 14:22–34. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ and Kuang WY: Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol. 21:1506–1514. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li SS, Yang S, Wang S, Yang XM, Tang QL and Wang SH: Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway. Oncol Rep. 26:1573–1579. 2011.PubMed/NCBI | |
|
Marin JJ, Castaño B, Blazquez AG, Rosales R, Efferth T and Monte MJ: Strategies for overcoming chemotherapy resistance in enterohepatic tumours. Curr Mol Med. 10:467–485. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Fang D and Hu J: MicroRNA and its roles in esophageal cancer. Med Sci Monit. 18:RA22–RA30. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S: Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shapira A, Livney YD, Broxterman HJ and Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Updat. 14:150–163. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko DD: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 112:1415–1424. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gao M and Karin M: Regulating the regulators: Control of protein ubiquitinationand ubiquitin-like modifications by extracellular stimuli. Mol Cell. 19:581–593. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Thrower JS, Hoffman L, Rechsteiner M and Pickart CM: Recognition of the polyubiquitin proteolytic signal. EMBO J. 19:94–102. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TY, Chen SA, Hung HY and Ou YY: Incorporating distant sequence features and radial basis function networks to identify ubiquitin conjugation sites. PLoS One. 6:e173312011. View Article : Google Scholar : PubMed/NCBI | |
|
Bielskienė K, Bagdonienė L, Mozūraitienė J, Kazbarienė B and Janulionis E: E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina. 51:1–9. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Cao J, Liu G and Huo JR: Function and mechanism of F-box proteins in gastric cancer (Review). Int J Oncol. 47:43–50. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y and Sun Y: Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des. 19:3215–3225. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Reed SI: Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol. 4:855–864. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Peters JM: The anaphase promoting complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell Biol. 7:644–656. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kipreos ET and Pagano M: The F-box protein family. Genome Biol 1: REVIEWS3002, 2000. Epub 2000 Nov 10. | |
|
Xie CM, Wei W and Sun Y: Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics. 40:97–106. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Lv L and Huo J: Roles of F-box proteins in human digestive system tumors (Review). Int J Oncol. 45:2199–2207. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J and Huo J: New insights into the mechanism of F-box proteins in colorectal cancer (Review). Oncol Rep. 33:2113–2120. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hartwell LH, Mortimer RK, Culotti J and Culotti M: Genetic control of the cell division cycle in yeast: V. Genetic analysis of cdc mutants. Genetics. 74:267–286. 1973.PubMed/NCBI | |
|
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bedford L, Lowe J, Dick LR, Mayer RJ and Brownell JE: Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 10:29–46. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Minella AC, Welcker M and Clurman BE: Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci USA. 102:9649–9654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. Embo J. 23:2116–2125. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hoeck JD, Jandke A, Blake SM, Nye E, Spencer-Dene B, Brandner S and Behrens A: Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci. 13:1365–1372. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rocher-Ros V, Marco S, Mao JH, Gines S, Metzger D, Chambon P, Balmain A and Saura CA: Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene. 29:2950–2961. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW and Wei W: Mcl-1 ubiquitination and destruction. Oncotarget. 2:239–244. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tong J, Tan S, Zou F, Yu J and Zhang L: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 36:787–796. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, Yu J and Zhang L: Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 77:2512–2521. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Zhou X, Bai W and Ma X: FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. Tumour Biol. 36:4197–4202. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J and Lee MH: Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Mol Cancer Ther. 14:1476–1487. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A and Aifantis I: The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 204:1825–1835. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med. 204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ding XQ, Zhao S, Yang L, Zhao X, Zhao GF, Zhao SP, Li ZJ and Zheng HC: The nucleocytoplasmic translocation and up-regulation of ING5 protein in breast cancer: A potential target for gene therapy. Oncotarget. 8:81953–81966. 2017.PubMed/NCBI | |
|
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. Asian Pac J Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Izumi D, Ishimoto T, Miyake K, Eto T, Arima K, Kiyozumi Y, Uchihara T, Kurashige J, Iwatsuki M, Baba Y, et al: Colorectal cancer stem cells acquire chemoresistance through the upregulation of F-Box/WD repeat-containing protein 7 and the consequent degradation of c-Myc. Stem Cells. 35:2027–2036. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Takeishi S and Nakayama KI: Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br J Cancer. 111:1054–1059. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M: p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Welcker M, Larimore EA, Frappier L and Clurman BE: Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol. 31:1214–1224. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R and Sterneck E: The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 29:4106–4117. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Moqadam Akbari F, Vrielink Oude JA, Agami R, Den Boer ML, Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle. 10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Sengupta T, Kukreja L and Minella AC: MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Jin W, Jia H, Yan J and Zhang G: MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI | |
|
Li R, Wu S, Chen X, Xu H, Teng P and Li W: miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. Am J Transl Res. 2016:2512–2524. 2016. | |
|
Ye M, Zhang Y, Zhang X and Zhang J, Jing P, Cao L, Li N, Li X, Yao L and Zhang J and Zhang J: Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res. 77:3527–3539. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Adua D, Di Fabio F, Ercolani G, Fiorentino M, Gruppioni E, Altimari A, Limpe Rojas FL, Normanno N, Pinna AD and Pinto C: Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. Mol Clin Oncol. 7:113–120. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, et al: Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget. 8:29771–29784. 2017.PubMed/NCBI | |
|
Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O and Negrini M: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer. 15:8082015. View Article : Google Scholar : PubMed/NCBI | |
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al: The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Demetrick DJ, Zhang H and Beach DH: Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet. 73:104–107. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM and Hershko A: Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 91:1745–1751. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuchi M, Masuda N, Nakajima M, Fukai Y, Miyazaki T, Kato H and Kuwano H: Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma. Anticancer Res. 24:777–783. 2004.PubMed/NCBI | |
|
Yang G, Ayala G and De Marzo A: Tian W, Frolov A, Wheeler TM, Thompson TC and Harper JW: Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 8:3419–3426. 2002.PubMed/NCBI | |
|
Traub F, Mengel M, Lück HJ, Kreipe HH and von Wasielewski R: Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 99:185–191. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rose AE, Wang G, Hanniford D, Monni S, Tu T, Shapiro RL, Berman RS, Pavlick AC, Pagano M, Darvishian F, et al: Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res. 24:197–206. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu HM, Liang Y, Chen Q, Wu QN, Guo YM, Shen GP, Zhang RH, He ZW, Zeng YX, Xie FY, et al: Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer. 30:204–212. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schüler S, Diersch S, Hamacher R, Schmid RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic cancer cells towards TRAIL induced apoptosis. Int J Oncol. 38:219–225. 2011.PubMed/NCBI | |
|
Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH and Wei W: Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 1:pii: 18702. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I and Hershko DD: The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 103:1336–1346. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Blagosklonny MV: Review Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle. 4:1693–1698. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang K, Zhang L, Zhang X, Tang H, Zhang J, Yan Y, Han K and Guo H: Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901. Int J Oncol. 50:2091–2100. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huang T, Yang L, Wang G, Ding G, Peng B, Wen Y and Wang Z: Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel. Onco Targets Ther. 10:439–446. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Davidovich S, Ben-Izhak O, Shapira M, Futerman B and Hershko DD: Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res. 10:R632008. View Article : Google Scholar : PubMed/NCBI | |
|
Schüler S, Diersch S, Hamacher R, Schmid RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int J Oncol. 38:219–225. 2011.PubMed/NCBI | |
|
Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L and Marks AR: Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 72:1836–1843. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Han F, Wu J, Lee SW, Chan CH, Wu CY, Yang WL, Gao Y, Zhang X, Jeong YS, et al: The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood. 118:5429–5438. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L and Pagano M: Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell. 4:799–812. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Müerköster S, Arlt A, Sipos B, Witt M, Grossmann M, Klöppel G, Kalthoff H, Fölsch UR and Schäfer H: Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 65:1316–1324. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Y, Zhang F, Zhao Y, Shao D, Zheng X, Chen Y, He K, Li J and Chen L: Berberine enhances chemosensitivity and induces apoptosis through dose-orchestrated AMPK signaling in breast cancer. J Cancer. 8:1679–1689. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW and Feng Y: Berberine suppresses cyclin D1 expression through proteasomal degradation in human hepatoma cells. Int J Mol Sci. 17:pii: E1899. 2016. View Article : Google Scholar | |
|
Harder B, Jiang T, Wu T, Tao S, de la Vega Rojo M, Tian W, Chapman E and Zhang DD: Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem Soc Trans. 43:680–686. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 32:3765–3781. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Woo Y, Oh J and Kim JS: Suppression of Nrf2 activity by chestnut leaf extract increases chemosensitivity of breast cancer stem cells to paclitaxel. Nutrients. 9:pii: E760. 2017. View Article : Google Scholar | |
|
Karathedath S, Rajamani BM, Aalam Musheer SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V, Velayudhan SR and Balasubramanian P: Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS One. 12:e01772272017. View Article : Google Scholar : PubMed/NCBI | |
|
Duong HQ, You KS, Oh S, Kwak SJ and Seong YS: Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1 and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants. 6:pii: E52. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chang KY, Hsu TI, Hsu CC, Tsai SY, Liu JJ, Chou SW, Liu MS, Liou JP, Ko CY, Chen KY, et al: Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. Redox Biol. 13:655–664. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu WH and Chang LS: Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol. 43:1708–1719. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu WD, Wang M, Ding HH and Qiu ZJ: FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells. Eur Rev Med Pharmacol Sci. 20:2551–2557. 2016.PubMed/NCBI | |
|
Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, Park SH, Im MJ, Choi J, Ryu J, et al: RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 311:48–56. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, et al: Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 19:2886–2897. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Coon TA, Glasser JR, Mallampalli RK and Chen BB: Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurora A, causing mitotic arrest. Cell Cycle. 11:721–729. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Lear T, Iannone O, Shiva S, Corey C, Rajbhandari S, Jerome J, Chen BB and Mallampalli RK: The proapoptotic F-box protein Fbxl7 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin. J Biol Chem. 290:11843–11852. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kamran M, Long ZJ, Xu D, Lv SS, Liu B, Wang CL, Xu J, Lam EW and Liu Q: Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis. 6:e2982017. View Article : Google Scholar : PubMed/NCBI | |
|
Lehman NL, Tibshirani R, Hsu JY, Natkunam Y, Harris BT, West RB, Masek MA, Montgomery K, van de Rijn M and Jackson PK: Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol. 170:1793–1805. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gütgemann I, Lehman NL, Jackson PK and Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu N, Nakajima N, Tsunematsu T, Ogawa I, Kawai H, Hirayama R, Fujimori A, Yamada A, Okayasu R, Ishimaru N, et al: Selective enhancing effect of early mitotic inhibitor 1 (Emi1) depletion on the sensitivity of doxorubicin or X-ray treatment in human cancer cells. J Biol Chem. 288:17238–17252. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, Manning G, Abraham RT and Hunter T: The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 35:442–453. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Katayama K, Noguchi K and Sugimoto Y: FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells. Cancer Sci. 104:694–702. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ravindranath AK, Kaur S, Wernyj RP, Kumaran MN, Miletti-Gonzalez KE, Chan R, Lim E, Madura K and Rodriguez-Rodriguez L: CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget. 6:26308–26321. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu B, Liu ZY, Cui J, Yang XM, Jing L, Zhou Y, Chen ZN and Jiang JL: F-box protein FBXO22 mediates polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int J Mol Sci. 18:pii: E212. 2017. View Article : Google Scholar | |
|
Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP and Lecker SH: The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 117:3940–3951. 2007.PubMed/NCBI | |
|
Tanaka N, Kosaka T, Miyazaki Y, Mikami S, Niwa N, Otsuka Y, Minamishima YA, Mizuno R, Kikuchi E, Miyajima A, et al: Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation. JCI Insight. 1:e836542016. View Article : Google Scholar : PubMed/NCBI | |
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lorenzi F, Babaei-Jadidi R, Sheard J, Spencer-Dene B and Nateri AS: Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Mol Ther Methods Clin Dev. 3:160242016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Han F, Li W, Yang Q, Zeng J, Jia J and Lui Z: F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. Oncotarget. 5:6178–6190. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huang HL, Zheng WL, Zhao R, Zhang B and Ma WL: FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 24:715–720. 2010.PubMed/NCBI | |
|
Liu J, Lv L, Gong J, Tan Y, Zhu Y, Dai Y, Pan X, Huen MS, Li B, Tsao SW, et al: Overexpression of F-box only protein 31 predicts poor prognosis and deregulates p38α- and JNK-mediated apoptosis in esophageal squamous cell carcinoma. Int J Cancer. 142:145–155. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kogo R, Mimori K, Tanaka F, Komune S and Mori M: FBXO31 determines poor prognosis in esophageal squamous cell carcinoma. Int J Oncol. 39:155–159. 2011.PubMed/NCBI | |
|
Guerrero-Garcia TA, Mogollon RJ and Castillo JJ: Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 62:12–16. 2017. View Article : Google Scholar : PubMed/NCBI |
